Investigator Initiated Multi-Site Clinical Trials (Collaborative R01)

The summary for the Investigator Initiated Multi-Site Clinical Trials (Collaborative R01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Investigator Initiated Multi-Site Clinical Trials (Collaborative R01): The support of multi-site clinical trials is one strategy NHLBI uses to improve the understanding of the clinical mechanisms of disease and to improve prevention, diagnosis, and treatment. The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for submitting grant applications for investigator-initiated multi-site randomized controlled clinical trials. The trials may address any research question related to the mission and goals of the NHLBI and may test clinical or behavioral interventions. The FOA is appropriate for applications to conduct phase II and phase III randomized clinical trials where participants are recruited from multiple sites. Large-scale pragmatic trials (such as comparative effectiveness trials) as well as trials designed to test efficacy of an intervention are appropriate. The trials may randomize at the individual (patient) level or at a group level (e.g., randomization of clinics, schools, worksites, etc.). Clinical trials involving NHLBI mission-related rare diseases that require coordination across multiple clinical sites are also suitable for submission to this FOA. In any case, the trial should propose the most efficient study design to complete the specific aims. For additional information about the mission, strategic plan, and research interests of the NHLBI, applicants are encouraged to consult the NHLBI website (http://www.nhlbi.nih.gov/about/strategicplan/index.htmThis Funding Opportunity Announcement is not intended for support of single-center studies or multicenter observational studies that are not testing an intervention. Clinical Coordination Center (CCC) and Data Coordination Center (DCC) applications are required to be submitted together when the proposed costs of the clinical trial exceed $500,000 (minus F&A for subcontracts) in any given year.

Federal Grant Title:	Investigator Initiated Multi-Site Clinical Trials (Collaborative R01)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-13-128
Type of Funding:	Grant
CFDA Numbers:	93.233
CFDA Descriptions:	National Center on Sleep Disorders Research
Current Application Deadline:	May 07, 2016
Original Application Deadline:	May 07, 2016
Posted Date:	Mar 01, 2013
Creation Date:	Mar 01, 2013
Archive Date:	Jun 07, 2016
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed
Grant Announcement Contact: NIH OER [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [[email protected]]
Similar Government Grants: • Cell and Gene Therapies for HIV Cure: Developing a Pipeline (P01 Clinical Trial Not Allowe...; • NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (...; • NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (...; • Predoctoral Training in Advanced Data Analytics for Behavioral and Social Sciences Researc...; • Cardiovascular Repository Type 1 Diabetes (CARE-T1D) Consortium (U01 Clinical Trial Not Al...; • Ancillary Studies in Clinical Trials (R01); • Opportunity PA-08-021; • Research Demonstration and Dissemination Grants (R18)
More Grants from the National Institutes of Health: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • NIDCR Predoctoral to Postdoctoral Transition Award to Promote a Diverse Dental, Oral and C...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...